Sarepta Therapeutics (SRPT) Share-based Compensation (2010 - 2026)

Sarepta Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 18.72% year-over-year to $33.7 million; the trailing twelve-month figure through Mar 2026 stood at $132.7 million (down 35.55% YoY), and the FY2025 full-year result was $139.1 million, down 32.2% from the prior year.
• Share-based Compensation for Q1 2026 stood at $33.7 million, down from $45.7 million in the prior quarter.
• The five-year high for Share-based Compensation was $102.9 million in Q2 2022, with the low at $16.4 million in Q3 2025.
• Average Share-based Compensation over 5 years is $47.0 million, with a median of $45.7 million recorded in 2025.
• Year-over-year, Share-based Compensation surged 254.8% in 2022 and tumbled 62.31% in 2025.
• Tracing SRPT's Share-based Compensation over 5 years: stood at $50.5 million in 2022, then slipped by 9.3% to $45.8 million in 2023, then soared by 53.96% to $70.5 million in 2024, then plunged by 35.24% to $45.7 million in 2025, then declined by 26.28% to $33.7 million in 2026.
• The last three Share-based Compensation figures came in at $33.7 million (Q1 2026), $45.7 million (Q4 2025), and $16.4 million (Q3 2025), per Business Quant data.

Peer Comparison